tiprankstipranks
Pharvaris N.V. (PHVS)
NASDAQ:PHVS
US Market
PHVS
Pharvaris
RESEARCH TOOLSreports
Want to see PHVS full AI Analyst Report?

Pharvaris (PHVS) Stock News & Sentiment

174 Followers
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
Premium
Company Announcements
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
9d ago
6K
PHVS
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
Premium
Company Announcements
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
10d ago
6K
PHVS
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
Premium
Ratings
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
1M ago
PHVS
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
Premium
Ratings
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
1M ago
PHVS
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
Premium
Market News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
1M ago
ANET
BCRX
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
Premium
Ratings
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
2M ago
PHVS
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
Premium
Company Announcements
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
2M ago
6K
PHVS
More PHVS News >

PHVS News on the Web

Top Pharvaris Insiders Quietly Cash Out in Major Stock Moves
TipRanks News
Neutral
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
TipRanks News
Bullish
Pharvaris price target raised to $33 from $31 at BofA
TipRanks News
Neutral
Why Pharvaris Shares Are Suddenly Sliding Today
TipRanks News
Bearish
Pharvaris (PHVS) Receives a Buy from H.C. Wainwright
TipRanks News
Neutral
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Allogene Therapeutics (ALLO)
TipRanks News
Neutral
Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Pharvaris (PHVS)
TipRanks News
Neutral
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
PHVS
Sector Average
Media Buzz
This Week3 articles
Weekly Average4.75 articles
News Sentiment
This Week59%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PHVS’s Media Buzz Sentiment?
3 articles about PHVS were published this week. In an average week, 4.75 articles are published.
    What is PHVS’s weekly average amount of articles?
    In an average week, 4.75 articles about PHVS are published.
      What is PHVS’s News Sentiment?
      59% of articles about PHVS were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        RLAYRelay Therapeutics
        GOSSGossamer Bio
        IMVTImmunovant
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week